Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trialsCOVID-19 폐렴으로 입원한 환자의 Tocilizumab: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-01-012022-09-11 Journal: Journal of investigative medicine : the official p [Category] SARS, 임상, 진단, [키워드] 28-day mortality administration Adult adverse events Analysis Anti-inflammatory anti-inflammatory agents Composite COVID-19 COVID-19 pneumonia death decrease distress Effectiveness Efficacy and safety evaluated hospitalized patient hospitalized patients incidence inhibitor mechanical ventilation Meta-analysis non-steroidal outcome patients hospitalized patients with COVID-19 performed Pneumonia Primary outcome Randomized controlled trial RCT RCTs receptor respiratory distress Respiratory distress syndrome risk risk ratio secondary outcome Secondary outcomes Serious Adverse Event Serious Adverse Events Standard of care statistically significant reduction syndrome systematic review Tocilizumab Treatment with COVID-19 [DOI] 10.1136/jim-2021-002001 PMC 바로가기 [Article Type] Meta-Analysis
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study건강한 성인에서 홍역 매개 SARS-CoV-2 백신 후보 V591/TMV-083의 안전성 및 면역원성: 무작위, 위약 대조 1상 연구 결과Clinical Trial Published on 2022-01-012022-09-11 Journal: EBioMedicine [Category] SARS, 임상, 치료기술, [키워드] adverse event adverse events age antibodies antibody Belgium binding antibodies Bioscience CEPI Chikungunya Coalition cohorts COVID-19 detectable dose Dose escalation double-blind evaluate expressing France healthy High dose high dose vaccine immune response Immunity immunogenicity Inc. injection Injections Innovation Intramuscular injection low dose low dose vaccine measles vector median Neutralizing antibodies neutralizing antibody participant performed phase Placebo placebo recipients placebo-controlled pre-fusion Randomized receiving reported responses Safety safety profile SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 vaccine screened Serious Adverse Event Serious Adverse Events Spike protein spike-specific T cell statistically significant subsidiary Support T cell T cell response T cell responses TCID THEMIS tissue culture treatment phase Trial Vaccine vaccine candidate vaccinee Volunteer was measured while [DOI] 10.1016/j.ebiom.2021.103810 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial성인에서 홍역 벡터 기반 SARS-CoV-2 백신 후보 V591의 안전성 및 면역원성: 1/2상 무작위, 이중 맹검, 위약 대조, 용량 범위 시험 결과Clinical Trial Published on 2022-01-012022-09-11 Journal: EBioMedicine [Category] SARS, 임상, 치료기술, [키워드] Adverse adverse events anti-SARS-CoV-2 assigned convalescent serum COVID-19 COVID-19 disease Culture Day death dose double-blind event fatigue headache healthy humoral immunogenicity immunogenicity Inc. infectious dose injection Injection-site pain Intramuscular injection median multicentre myalgia neutralising antibody occurred Older participant Placebo placebo-controlled randomised response Safety SARS-CoV-2 SARS-CoV-2 vaccine screened secondary secondary outcome Serious Adverse Event Serious Adverse Events serum Sharp single dose subsidiary TCID tissue tissue culture titre titres Trial USA Vaccine [DOI] 10.1016/j.ebiom.2021.103811 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 Vaccination for Frail Older Adults in Singapore – Rapid Evidence Summary and Delphi Consensus Statements싱가포르의 허약한 노인을 위한 COVID-19 예방 접종 - 신속한 증거 요약 및 델파이 합의 선언문Article Published on 2022-01-012022-09-11 Journal: The Journal of Frailty & Aging [Category] 임상, [키워드] administration Adults adverse event article clinical trials conducted Consensus content controlled trials COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines DelPhi dose Effectiveness Efficacy Efficacy and safety elderly elicit Evidence frail Future Geriatrician Google Scholar hand include Life expectancy Moderna Older older adult Older adults participant Patient Pfizer-BioNTech phase Randomized Randomized controlled trials Rapid recommendation reference reported Serious Adverse Events Singapore thought Trial vaccination Vaccine vaccine efficacy Vaccines Web of Science [DOI] 10.14283/jfa.2022.12 PMC 바로가기 [Article Type] Article
Nebulized enriched heparin to treat no critical patients with Sars-Cov-2 Triple-blind clinical trialSars-Cov-2 삼중 맹검 임상 시험에서 중증 환자를 치료하지 않는 분무 농축 헤파린6700 Published on 2021-12-232022-09-10 Journal: Medicine [Category] 변종, 신약개발, 임상, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus 2 advance antiviral activity Antiviral agents ARMS both groups clinical protocol Clinical tests clinical trial collapse conducted coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 Critical Diagnosis disease drug Efficacy group health systems heparin In vitro assay inhalation Intervention mechanism nebulized new virus outcome pandemic status participant Patient Placebo Pneumonia protocols Radiological Diagnosis receive Replication respiratory Respiratory disease SARS-CoV-2 selected Serious Adverse Events Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus shown Spread therapeutic approaches treat Treatment triple-blind urgency Vaccine variant Viral Viral load viral respiratory [DOI] 10.1097/MD.0000000000028288 PMC 바로가기 [Article Type] 6700
Association of COVID-19 with Intracranial Hemorrhage during Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A 10-Year Retrospective Observational StudyArticle Published on 2021-12-222022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] accompanied acute respiratory distress acute respiratory distress syndrome ARDS association causes Computed tomography COVID-19 Cox regression analysis cranial ECMO etiologies Extracorporeal extracorporeal membrane oxygenation Factor hemorrhage Hemorrhagic Stroke identify incidence Intracerebral hemorrhage Intracranial membrane Neurologic complications occur Oxygenation Patient patients treated patients with ARDS patients with COVID-19 performed receiving respiratory Retrospective analysis risk Serious Adverse Events single-center study period Support syndrome target therapeutic interventions was used [DOI] 10.3390/jcm11010028 PMC 바로가기 [Article Type] Article
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study미국에서 Covid-19 회복기 혈장의 접근 및 안전성 확장 접근 프로그램 : 전국 레지스트리 연구Clinical Trial Published on 2021-12-202022-09-10 Journal: PLoS Medicine [Category] SARS, 신약개발, 임상, 진단, [키워드] 30-day mortality rate 95% CI access acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Administered affected age Analysis approval blood collection causative agent central institutional review board changes in characteristics of patient Clinical characteristics clinical trials convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma demographic demographic and clinical characteristics demographic group demographic groups early stage early stages effective effort eligible patient Eligible patients Emerging infectious disease enrolled Enrollment Evidence example Expanded access Expanded Access Program Factor framework Hispanic ethnicity hospital Hospitalized hospitalized patient hospitalized patients incidence include Inclusion increases in Infection infection rate Infectious disease initiated institutional review board investigated investigator less life-threatening Local majority male Mayo Clinic Metrics mortality rate National obesity observational study Older overweight Patient plasma populations potential therapeutic agents Pragmatic progression provided public health public health emergency Racial randomized clinical trial Region regions registry data regulatory pathway regulatory pathways required researcher respiratory resulting risk Safe safety profile SARS-CoV-2 Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus Spread Stage Study design Temporal the United State The United States therapy transfused transfusion Treatment treatment effects Trial registration United State United States website while widespread with COVID-19 [DOI] 10.1371/journal.pmed.1003872 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성Clinical Trial Published on 2021-12-182022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, [키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type [DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants이종 Chadox1 NCOV-19 및 BNT162B2 프라임-부스트 백신 접종은 유능한 SARS-COV-2 변이체에 대한 강력한 중화 항체 반응 및 T 세포 반응성을 유도합니다.Clinical Trial Published on 2021-12-172022-08-13 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] addition Administered Adverse reactions All participants Alpha analysed antibody titres ART Arts B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta BNT162b2 boost CD4 CD8 Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 COVID-19 vaccination Delta dominant elicit elicited European evaluate finding followed by foundation funding Gamma Germany Heterologous heterologous vaccination homologous Horizon humoral immune immune responses Immunity immunogenic Immunological response immunological responses individual induce Lower median mRNA-based vaccine mRNA-based vaccines nCoV neutralization neutralized Neutralizing activity Neutralizing antibody response no difference offer P.1 participant peptide peptides prevalent Protective reactive reactivity reactogenicity receiving recognize regimen Research resulting retained Robert Koch SARS-CoV-2 spike peptide SARS-CoV-2 variant SARS-CoV-2 variants Science sera Serious Adverse Event Serious Adverse Events serological data significantly Symptom T cell T cells tested titre union vaccination variant variants variants of concern Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.ebiom.2021.103761 PMC 바로가기 [Article Type] Clinical Trial
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsArticle Published on 2021-12-142022-10-04 Journal: Nature Communications [Category] SARS, 유전자 메커니즘, 임상, 치료법, [키워드] Adults adverse event age antibody BNT162b2 BNT162b2 vaccine COVID-19 vaccine dose doses evaluate event geometric geometric mean titer groups healthy immune response individual interim analysis Intramuscular injection Japanese local reaction Mild moderate Neutralizing of BNT162b2 Older age participant Phase I trials Placebo Randomized randomized study receive recipient RNA vaccines robust safety profile SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events serum stratified [DOI] 10.1038/s41467-021-27316-2 PMC 바로가기 [Article Type] Article